A multicenter, randomized, placebo-controlled trial for cilostazol in patients with mild cognitive impairment: The COMCID study protocol

INTRODUCTION: There are currently no effective treatments preventing conversion from mild cognitive impairment (MCI) to Alzheimer's disease. Cilostazol is a selective type-3 phosphodiesterase inhibitor that ameliorates accumulation of amyloid-β and has prevented cognitive decline in rodent mode...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Alzheimers Dement (N Y)
Hlavní autoři: Saito, Satoshi, Kojima, Shinsuke, Oishi, Naoya, Kakuta, Ryosuke, Maki, Takakuni, Yasuno, Fumihiko, Nagatsuka, Kazuyuki, Yamamoto, Haruko, Fukuyama, Hidenao, Fukushima, Masanori, Ihara, Masafumi
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2016
Témata:
Featured Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5651350/
https://ncbi.nlm.nih.gov/pubmed/29067312
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2016.10.001
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky